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Resveratrol augments ER stress and the cytotoxic
effects of glycolytic inhibition in neuroblastoma by
downregulating Akt in a mechanism independent
of SIRT1
Regina M Graham1, Fiorela Hernandez2,4, Nataly Puerta3,5, Guillermo De Angulo2, Keith A Webster3 and
Steven Vanni1
Cancer cells typically display increased rates of aerobic glycolysis that are correlated with tumor aggressiveness and a poor
prognosis. Targeting the glycolytic pathway has emerged as an attractive therapeutic route mainly because it should spare normal
cells. Here, we evaluate the effects of combining the inhibition of glycolysis with application of the polyphenolic compound
resveratrol (RSV) in neuroblastoma (NB) cancer cell lines. Inhibiting glycolysis with 2-deoxy-D-glucose (2-DG) signiﬁcantly
reduced NB cell viability and was associated with increased endoplasmic reticulum (ER) stress and Akt activity. Administration
of 2-DG increased the expression of the ER molecular chaperones GRP78 and GRP94, the prodeath protein C/EBP homology
protein (CHOP) and the phosphorylation of Akt at S473, T450 and T308. Combined treatment with both RSV and 2-DG reduced
GRP78, GRP94 and Akt phosphorylation but increased CHOP and NB cell death when compared with the administration of
2-DG alone. The selective inhibition of Akt activity also decreased 2-DG-induced GRP78 and GRP94 expression and increased
CHOP expression, suggesting that Akt can modulate ER stress. Protein phosphatase 1α (PP1α) was activated by RSV,
as indicated by a reduction in PP1α phosphorylation at T320. Pretreatment of cells with tautomycin, a selective PP1α inhibitor,
prevented the RSV-mediated decrease in Akt phosphorylation, suggesting that RSV enhances 2-DG-induced cell death by
activating PP1 and downregulating Akt. The RSV-mediated inhibition of Akt in the presence of 2-DG was not prevented by the
selective inhibition of SIRT1, a known target of RSV, indicating that the effects of RSV on this pathway are independent of
SIRT1. We propose that RSV inhibits Akt activity by increasing PP1α activity, thereby potentiating 2-DG-induced ER stress and
NB cell death.
Experimental & Molecular Medicine (2016) 48, e210; doi:10.1038/emm.2015.116; published online 19 February 2016
INTRODUCTION
Neuroblastoma (NB), which is presumed to arise from
neuronal precursor cells that originate from the neural crest
during embryonic development, is the most common pediatric
extracranial tumor and the fourth most common malignancy
during childhood. NB affects very young children, with
approximately one-third of affected children diagnosed in
infancy and two-thirds diagnosed by the age of 5 years. More
than half of affected children over the age of 1 year have
metastatic disease at the time of diagnosis.1 In children without
metastatic disease or infants under the age of 18 months, the
prognosis is very good. However, the prognosis for high-risk
patients is extremely poor, and these include children with
MYCN-ampliﬁed tumors, unfavorable tumor biology and/or
the presence of distant metastasis. Despite aggressive multi-
modal treatment including surgery, high-dose chemotherapy,
radiotherapy and stem cell transplant followed by retinoid
maintenance therapy, these children often relapse and succumb
to the disease. Newer therapies, including treatment with an
anti-GD2 antibody in combination with retinoic acid, and
multiple ongoing clinical trials offer some hope; however, the
effects of aggressive treatment regimens induce signiﬁcant
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morbidity and, as a result, children may not qualify for
additional clinical trials.2 This underscores the need for more
effective and less toxic treatment options.
The fact that cancer cells display increased aerobic glycolysis
compared with normal cells is known as the Warburg effect.
This effect has been exploited for imaging tumors using
ﬂuorodeoxyglucose positron emission tomography for many
years. Fluorodeoxyglucose is an analog of glucose that is rapidly
taken up by highly glycolytic cancer cells. The use of
ﬂuorodeoxyglucose positron emission tomography is increasing
in NB, conﬁrming the glycolytic nature of these tumors.3 The
activation of oncogenes, the loss of tumor suppressors and
the hypoxic tumor microenvironment all contribute to the
upregulation of glycolysis. In addition to generating adenosine
triphosphate, glycolysis confers several advantages that con-
tribute to cancer cell survival. Glycolysis generates intermedi-
ates such as nucleotides, amino acids and lipids that are needed
for rapidly proliferating cells. Furthermore, the secretion of
lactic acid, a by-product of glycolysis, leads to an acidic
microenvironment that promotes cell death of surrounding
cells, extracellular matrix degradation, angiogenesis and the
inhibition of immune response.4 Glycolysis also promotes
cancer cell survival and chemoresistance by maintaining
cellular adenosine triphosphate at levels that are required for
drug efﬂux, drug inactivation, DNA repair and anti-death cell
signaling pathways.5 The therapeutic targeting of tumor cell
metabolism is a growing area of investigation. Because of
the striking metabolic differences between cancer cells and
noncancer cells, targeting aspects of cancer metabolism may be
the ideal treatment because it should limit toxicity to
normal cells.
One of the best-studied glycolytic inhibitors is the glucose
analog 2-deoxy-D-glucose (2-DG). Like glucose, 2-DG is taken
up by cancer cells via glucose transporters (GLUTs) and is
phosphorylated by hexokinase II. However, unlike glucose-6-
phosphate, 2-DG-phosphate cannot be further metabolized,
and it therefore accumulates in the cell, leading to allosteric
inhibition of hexokinase II and glucose utilization. Using 2-DG
has been shown to inhibit cell proliferation and to induce cell
death both in vitro and in vivo.6–8 Recently, it was demon-
strated that 2-DG could induce endoplasmic reticulum (ER)
stress and its adaptive response pathway, known as the
unfolded protein response (UPR).9 Owing to the structural
similarity between 2-DG and mannose, 2-DG is erroneously
incorporated into the oligosaccharide chain of N-linked
glycosylation, leading to the accumulation of misfolded pro-
teins and the activation of the UPR.9 The glucose-related
proteins (GRPs) GRP78 and GRP94 are ER-localized molecular
chaperones that assist in protein folding and assembly and play
important roles in cell survival during brief periods of ER
stress.10 However, when ER stress is sustained, the UPR
switches from adaption to cell death. A key protein in this
pathway is the transcription factor C/EBP homology protein
(CHOP), also known as growth arrest- and DNA damage-
inducible gene 153. CHOP promotes cell death by modulating
the expression of members of the BCL-2 family.11 Targeting
the UPR by promoting the accumulation of misfolded proteins
and/or by inhibiting the adaptive mechanisms of the UPR is
currently under investigation for cancer therapy.
In the clinical arena, 2-DG has been shown to be safe and
has demonstrated potential when combined with chemo-
therapy or radiotherapy. Combining 2-DG and radiotherapy
resulted in modestly increased survival and a signiﬁcant
enhancement in the quality of life in patients with malignant
gliomas.12 More recently, a combination of 2-DG and
docetaxel was well tolerated, and of the 34 patients with
advanced solid tumors, 1 had a partial response and 11 had
stable disease.13 These clinical trials and multiple preclinical
studies suggest that 2-DG may be most effective when
combined with additional anticancer agents.14
Resveratrol (RSV), a plant-derived polyphenolic compound
found in grape skin, some berries and peanuts, has exhibited
anticancer effects both in vitro and in vivo. The chemopreven-
tive and therapeutic potential of RSV has been demonstrated in
multiple cancers including skin, breast, prostate and lung
cancer as well as NB.15 RSV has emerged as a promising
anticancer agent because it has the ability to modulate multiple
signaling pathways involved in cancer cell proliferation and
survival.16 In NB, RSV has been shown to inhibit cell cycle,
promote mitochondrial dysfunction, activate caspases and
induce apoptosis.17 Furthermore, RSV signiﬁcantly reduced
tumor growth in NB xenograft models and increased the anti-
GD2 immunotherapy response in NXS2 tumor-bearing mice.18
One pathway modulated by RSV is the phosphatidylinositol
3-kinase (PI3K)/Akt pathway that has been shown to play a
central role in apoptosis avoidance, tumor progression and
resistance to chemo- and radiotherapy. The activity of Akt is
dependent on its phosphorylation that is regulated by multiple
phosphatases. PTEN (phosphatase and tensin homolog)
dephosphorylates PIP3 (phosphatidylinositol (3,4,5)-tripho-
sphate), preventing PI3K and subsequent Akt activation. The
loss of this tumor suppressor has been observed in several
cancers and is often correlated with a poor prognosis.19
However, Akt can also be dephosphorylated directly by protein
phosphatase 2A (PP2A), protein phosphatase 1 (PP1) and
PHLPP (PH domain leucine-rich repeat protein phosphatase).
Recently, it was demonstrated that the adaptor protein
PINCH1 (particularly interesting new cysteine-histidine-rich 1)
is upregulated in many cancers and contributes to radio-
resistance by binding to and inhibiting PP1, resulting in
increased Akt activity.20
In the present study, we aimed to determine the effects of
2-DG, either alone or in combination with RSV, on multiple
NB cell lines generated from children with advanced NB.
Clinically relevant concentrations of 2-DG signiﬁcantly reduced
viability in all NB cell lines. Furthermore, combining RSV with
2-DG signiﬁcantly increased NB cell death compared with
using 2-DG alone. The mechanism of action of RSV involves
decreased Akt activity and potentiated 2-DG-induced ER stress
that is independent of SIRT1 activity.
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MATERIALS AND METHODS
Cell culture and reagents
All cells were maintained at 37 °C in a humidiﬁed 5% CO2 incubator.
The neuroblastoma cell lines SK-N-SH, SH-SY5Y, SK-N-Be2 and
SMS-KCNR were obtained from American Type Culture Collection
(ATCC, Manassas, VA, USA). NB1691 was generously provided by Dr
Andrew Davidoff (St Jude’s Children’s Research Hospital, Memphis,
TN, USA). These cell lines were cultured in RPMI-1640 supplemented
with 10% heat-inactivated fetal bovine serum and 1% penicillin–
streptomycin. SVBM15 cells were isolated from the bone marrow of a
relapsed neuroblastoma patient and cultured in DMEM/F12+Gluta-
MAX supplemented with 2% B27, 10% heat-inactivated fetal bovine
serum and 1% penicillin–streptomycin. Brieﬂy, bone marrow aspirate
was mixed 1:3 with phosphate-buffered saline and layered over Ficoll
(Sigma-Aldrich, St Louis, MO, USA) and centrifuged at 445 g for
30 min. The cells at the interphase layer were collected, pelleted,
washed 1× with media and plated onto collagen-coated 100 mm
plates. Cells were monitored using light microscopy, and identiﬁcation
was veriﬁed by staining for the disialoganglioside GD2, an antigen that
is expressed on tumors of neuroectodermal origin,21 using NB84
monoclonal antibody from Leica (Supplementary Figure 1). Cell lines
were routinely tested for mycoplasma using either a MycoAlert
mycoplasma detection kit (Lonza, Walkersville, MD, USA) or a
LookOut mycoplasma PCR detection kit (Sigma) according to the
manufacturer’s instructions. The reagents 2-DG, RSV, mannose and
tautomycin were obtained from Sigma; 17-N-allylamino-17-
demethoxygeldanamycin (17-AAG) was obtained from LC Labora-
tories (Woburn, MA, USA); and EX-527 was obtained from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Wortmannin, LY294002,
insulin-like growth factor (IGF) and insulin were obtained from R&D
Systems (Minneapolis, MN, USA).
Cell viability
CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS)
was obtained from Promega (Madison, WI, USA), and viability was
determined according to the manufacturer’s instructions. At 16 h
before drug treatment, ∼ 5000–10 000 NB cells per well were plated
into 96-well plates. RSV and 2-DG were freshly prepared in ethanol
and water, respectively, before each experiment. Cell viability was
determined after 72 h of drug exposure. Experiments were repeated at
least 3 times.
Western blot assays
Cells were lysed in ice-cold RIPA buffer (1% sodium deoxycholate,
0.1% SDS, 1% Triton X-100, 10 mM Tris pH 8 and 140 mM NaCl)
supplemented with 250 μnits per ml Benzonase, 1 mM dithiothreitol
and phosSTOP phosphatase inhibitor cocktail and a cOmplete protease
inhibitor cocktail (both from Roche, Indianapolis, IN, USA). All other
reagents were obtained from Sigma. Proteins were quantiﬁed using a
BCA protein assay (Thermo Scientiﬁc, Waltham, MA, USA) and
proteins (20 μg per sample) were separated using SDS–polyacrylamide
gel electrophoresis and electroblotted to nitrocellulose membranes (Bio-
Rad, Hercules, CA, USA). Membranes were stained with Ponceau Red
to monitor the transfer of proteins and then blocked with 5% non-fat
dry milk (Bio-Rad). Membranes were probed with anti-Grp94 (Enzo
Life Sciences, Farmingdale, NY, USA), anti-grp78, anti-CHOP/
Gadd153, anti-phospho-Akt (T308, T450 and S473), anti-pan Akt,
anti-phospho-GSK3β (S9), anti-GSK3β, anti-phospho-IRS-1 (Y632),
anti-IRS-1, anti-survivin, anti-phospho-PP1α (T380), anti-PP1α (all
obtained from Cell Signaling Technology, Danvers, MA, USA), anti-α-
tubulin (Abcam, Eugene, OR, USA) and anti-β-actin (Chemicon,
Temecula, CA, USA) antibodies. Following incubation with primary
antibodies, membranes were washed, reacted with horseradish perox-
idase–conjugated secondary antibodies and visualized using enhanced
chemiluminescence (Thermo Scientiﬁc). For some experiments, band
intensities were quantiﬁed using Image J (NIH, Bethesda, MD, USA).
Co-immunoprecipitation assays
Following treatment, cells were harvested in ice-cold immunoprecipita-
tion buffer (20 mM Tris-HCl pH 8.0, 137 mM NaCl, 2 mM EDTA, 1%
Triton X-100 and 10% glycerol). Then, 500 μg of protein was
immunoprecipitated overnight at 4 °C using anti-PI3K p85
(EMD Millipore, Billerica, MA, USA). Antibody–protein complexes
were incubated for an additional 2 h with TrueBlot (Rockland
antibodies and assays, Limerick, PA, USA) and then washed 5× with
immunoprecipitation buffer or phosphate-buffered saline. Co-
immunoprecipitated proteins were analyzed using western blot analysis.
Statistical analysis
Cell viability data were analyzed using Student’s t-tests for all pairwise
comparisons of the different treatments that were tested. The results
are presented as the mean± s.e.m.
RESULTS
2-DG causes dose-dependent growth inhibition in NB
cell lines
To determine the effect of 2-DG on NB cell viability, we
exposed six NB cell lines to increasing concentrations of 2-DG
(0–8mM) and determined the half-maximal inhibitory con-
centration (IC50) for each cell line. The IC50 was found to
range between 1.87 and 5.4 mM, with a median IC50 of 2.1 mM.
Cell line information and associated IC50 data are shown in
Figure 1a. N-MYC protein levels were examined using western
blot analysis (Figure 1b). The ampliﬁcation of MYCN did not
affect sensitivity of the NB cells to 2-DG; this ﬁnding is in
agreement with a previous study that demonstrated that the
rate of glycolysis in NB cells is not related to their MYCN
status.22
Figure 1 2-Deoxy-D-glucose (2-DG) reduces cell viability in
neuroblastoma (NB) cell lines independent of NMYC status. (a) Cell
line characteristics and the half-maximal inhibitory concentration
(IC50) of 2-DG in six NB cell lines. Amp, MYCN ampliﬁed; BM,
bone marrow. (b) Western blot analysis showing N-Myc protein
levels. No correlation was observed between N-Myc status and
susceptibility to 2-DG (n=3).
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2-DG induces UPR in neuroblastoma cell lines
Phase II clinical trials have indicated that 2-DG is minimally
effective as a single agent. Therefore, to identify other possible
therapeutic targets that may enhance the effectiveness of 2-DG
in NB, we examined cell stress and survival signaling pathways
that were induced by 2-DG treatment. In certain cell types, a
low dose of 2-DG induced ER stress and the UPR.9,23 To
examine the effects of 2-DG on ER stress and the UPR, NB
cells were exposed to 2mM 2-DG for 8 or 24 h, and the levels
of the known UPR markers GRP78, GRP94 and CHOP were
quantiﬁed using western blot analysis. An increase in at least
two of these markers was observed in NB cells, with GRP78
being robustly induced in all of the cell lines (Figure 2a),
indicating that 2-DG induces the UPR in NB. To determine
whether 2-DG induces UPR by interfering with N-linked
glycosylation, NB1691 and SK-N-BE2 cells were exposed to
2-DG with or without mannose, an N-linked glycosylation
precursor. Exogenously supplied mannose prevented
2-DG-induced induction of GRP78, suggesting that 2-DG
induces the UPR by interfering with N-linked glycosylation
(Supplementary Figure 2). GRP78 and GRP94 are ER-localized
molecular chaperones that play important roles in cell survival
following ER stress.10 To determine whether inhibition of the
UPR potentiated the 2-DG-induced loss in cell viability,
NB cells were treated with 17-AAG, a GRP94 inhibitor, in
combination with 2-DG, and cell viability was analyzed after
72 h of treatment. The addition of 17-AAG to 2-DG signiﬁ-
cantly decreased cell viability compared with the effect of 2-DG
Figure 2 2-Deoxy-D-glucose (2-DG) induces endoplasmic reticulum (ER) stress. (a) Neuroblastoma (NB) cell lines were treated with 2 mM
2-DG for 8 or 24 h, and the levels of the unfolded protein response (UPR) markers GRP78, GRP94 and C/EBP homology protein (CHOP)
were then determined using western blot analysis. (b) NB cells were treated with 500 nM 17-N-allylamino-17-demethoxygeldanamycin
(17-AAG), 2-DG (0.5 and 2 mM) or both, and cell viability was determined using MTS assays (n=3). *Po0.05 compared with
vehicle-treated controls, #Po0.05 for treatment with 17-AAG+2-DG compared with treatment with 2-DG alone.
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alone in all NB cell lines (Po0.05; n= 3). Combined applica-
tion of 2-DG and 17-AAG (500 nM) decreased cell viability by
an average of 35± 1.9% (0.5 mM 2-DG) and 31± 5.5% (2mM
2-DG) compared with the viability of cells treated with only
2-DG (Figure 2b).
2-DG induces the IRS-1/PI3K/Akt signaling pathway
The serine/threonine kinase Akt regulates key cellular pro-
cesses, including cell growth, survival and metabolism, and is
therefore an attractive therapeutic target for NB. In different
studies, glycolytic inhibitors have been shown to either increase
or decrease Akt activity.24,25 To examine the effect of 2-DG on
Akt signaling in NB, we treated NB1691 cells with 2 mM 2-DG
for 0–8 h and examined Akt phosphorylation at threonine 308
(T308), 450 (T450) and serine 473 (S473) using western blot
analysis. Application of 2-DG induced a rapid and robust
increase in the phosphorylation of Akt at all examined residues
(Figure 3a). An increase in Akt phosphorylation was observed
as early as 30min after exposure to 2 mM 2-DG, and it
remained elevated for at least 8 h. Furthermore, after 2 h of
2-DG treatment, we observed an increase in the phosphoryla-
tion of insulin receptor substrate 1 (IRS-1) at tyrosine 632
(Y632), a site that is necessary for full IRS-1 activation.26 IRS-1
is a major substrate for both the insulin receptor and IGF-1R
Figure 3 2-Deoxy-D-glucose (2-DG) activates the Akt signaling pathway independent of serum growth factors. (a) NB1691 cells were
treated with 2 mM 2-DG for the indicated times, and the levels of phosphorylation of insulin receptor substrate 1 (IRS-1; Y632) and Akt
(T308, T450, S473) were determined using western blot analysis. (b) NB1691 cells were treated with and without 2 mM 2-DG for 2 h.
Cell lysates were immunoprecipitated using an anti-IRS-1 antibody and then immunoblotted using an anti-PI3K p85 antibody.
(c) Schematic showing the activation of the Akt pathway by insulin and insulin-like growth factor 1 (IGF-1). (d) The effects of serum
growth factors, insulin or IGF-1 on 2-DG-induced Akt phosphorylation were evaluated in NB1691 cells. In the serum-free experiments,
cells were starved overnight in serum-free media and then treated with 2 mM 2-DG (in serum-free media) for 4 h with or without insulin
(100 ng ml−1) or IGF-1 (100 ng ml−1). A no-glucose control, shown in lane 5 (− ), has been included. These cells were incubated in
serum-free and glucose-free medium for 4 h before harvest. Two exposures are shown, for better clarity. (e) Neuroblastoma (NB) cells were
treated with phosphatidylinositol 3-kinase (PI3K) inhibitors (10 μM wortmannin or 10 μM LY294002), 2-DG (0.5 and 2 mM) or both, and
viability was determined using MTS assays (n=3). *Po0.05 compared with vehicle-treated controls, #Po0.05 for treatment with Akt
inhibitor+2-DG compared with treatment with 2-DG alone.
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(Figure 3c). Activated IRS-1 binds and activates PI3K, leading
to an increase in the level of PIP3 that is followed by
the recruitment and activation of PDK-1 (phosphoinositide-
dependent kinase-1) and Akt. To determine whether 2-DG
promoted IRS-1 binding to PI3K in NB cells, we performed
immunoprecipitation pulldown assays using IRS-1 and the
PI3K regulatory subunit p85. After 2 h of 2-DG treatment,
PI3K pulldown was signiﬁcantly increased, conﬁrming the
activation of the IRS-1/PI3K/Akt pathway (Figure 3b).
The role of growth factor signaling in 2-DG-mediated
activation of Akt is controversial.27,28 To determine whether
growth factors are necessary for 2-DG-induced phosphoryla-
tion of Akt in NB, cells were serum starved overnight, washed
again in serum-free media and treated with 2mM 2-DG for 4 h,
and the levels of phospho-Akt were examined using western
blot analysis. Akt phosphorylation (at T308 and S473) was
induced by 2-DG irrespective of whether serum was present or
absent. As a control, we included a glucose-free condition
(Figure 3d, lane 5 that is indicated by a negative sign (− )).
Here, cells were serum starved overnight and then incubated in
serum- and glucose-free media for 4 h. Similar to the effect of
2-DG, the lack of glucose also induced Akt phosphorylation in
the absence of serum growth factors, indicating that serum
growth factors are not required to activate the Akt pathway
under glucose-limiting conditions. However, the addition of
either IGF-1 or insulin greatly enhanced 2-DG-induced
levels of phospho-Akt (Figure 3d). These data suggest that
although serum growth factors are not required for the
2-DG-induced activation of Akt, its response is ampliﬁed by
IGF-1 or insulin.
Figure 4 Resveratrol (RSV) attenuates 2-deoxy-D-glucose (2-DG)-induced Akt and potentiates endoplasmic reticulum (ER) stress.
To determine the effects of combining 2-DG with RSV on the Akt pathway and unfolded protein response (UPR) markers, NB1691 cells
were treated with 2 mM 2-DG and RSV (10, 25, 50 or 100 μM) for 8 h and then examined using western blot analysis. (a) Western blot
analysis showing the levels of phospho-Akt (T450, T308 and S473), phospho-PP1α (T320) and survivin. (b) Densitometry results showing
the ratio of phosphorylated to total Akt and the ratio of phosphorylated protein phosphatase 1α (PP1α) to total PP1α; arbitrary units
(n=3). #Po0.05 compared with nontreated controls; *Po0.05 compared with treatment with 2-DG treated alone. (c) Western blot
analysis showing the levels of the UPR markers GRP78, GRP94 and C/EBP homology protein (CHOP). (d) To determine the effect of Akt
on the UPR, NB1691 cells were treated with 10 μM wortmannin before treatment with 2 mM 2-DG treatment for 8 h, and the levels of
phospho-Akt (T308, S473), GRP78, GRP94 and CHOP were evaluated using western blot analysis.
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Inhibiting Akt increases the cytotoxicity of 2-DG
To determine the functional consequences of 2-DG-induced
activation of Akt in NB, cell lines were exposed to 0.5 or 2 mM
2-DG with or without the PI3 kinase inhibitors wortmannin
or LY294002. In NB1691 cells, PI3K inhibition by either
wortmannin or LY294002 attenuated 2-DG-induced phos-
phorylation of Akt and its downstream target GSK3β
(Supplementary Figure 3A) and reduced cell viability more
than application of 2-DG alone (Supplementary Figure 3B).
Furthermore, PI3K inhibition signiﬁcantly decreased cell
viability compared with application of 2-DG alone in all tested
NB cell lines (Po0.05; n= 3). PI3K inhibition decreased
viability by an average of 34±2.3% and 39± 4.6% in cells
treated with 0.5 and 2mM 2-DG (Figure 3e), respectively,
compared with the use of 2-DG alone.
RSV attenuates 2-DG-induced Akt activation and potentiates
ER stress
RSV has been shown to promote cell death by modulating
cell survival signaling pathways and the levels of apoptosis
regulators, such as Akt, ERK (extracellular signal-regulated
kinase), p53, Bcl-2, IAP (inhibitor of apoptosis) and TRAIL
(tumor necrosis factor-related apoptosis-inducing ligand).16
To determine the effect of RSV on 2-DG-induced Akt
phosphorylation, we exposed NB1691 cells to increasing
concentrations of RSV (10–100 μM) in the presence or absence
of 2-DG for 8 h and then examined phospho-Akt levels. RSV
decreased 2-DG-induced phosphorylation of Akt at T308, T450
and S473 and decreased the level of survivin, a prosurvival
protein that has previously been shown to be regulated by Akt
(Figure 4a). Quantiﬁcation of Akt phosphorylation revealed
that 2-DG signiﬁcantly increased the level of phospho-T308
(by 7.2-fold) and phospho-S473 (by 11.6-fold) compared with
untreated controls. Furthermore, RSV treatment reduced T450,
T308 and S473 phosphorylation. Importantly, all concentra-
tions of RSV signiﬁcantly reduced phosphorylation at S473,
and this site is known to be required for the full activation
of Akt (Figure 4b). To determine whether this was a cell
line-speciﬁc effect, we also examined the effect of RSV on
Figure 5 Resveratrol (RSV) enhances 2-deoxy-D-glucose (2-DG)-induced cell death. The effect of 10 μM RSV on 2-DG (0.5 and 2 mM)-
treated NB1691 cells was examined using western blot analysis after 48 h. (a) RSV promoted the cleavage of α-fodrin (indicated by 150
and 120 kDa fragments) and caspase-3 (indicated by 19 and 17 kDa fragments), demonstrating the activation of caspase activity. (b) The
effect of combining RSV (10 μM) and 2-DG (0.5 and 2 mM) on cell viability was analyzed using MTS assays after 72 h. RSV signiﬁcantly
increased 2-DG-induced cell death (n=3). *Po0.05 compared with vehicle-treated controls, #Po0.05 for treatment with RSV+2-DG
compared with treatment with 2-DG alone.
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2-DG-induced Akt phosphorylation and the level of survivin
in three additional NB cell lines, SH-SY5Y, SK-N-SH and
SK-N-BE2, and observed similar results (Supplementary
Figures 4A–C).
RSV has been demonstrated to both inhibit and promote ER
stress.29–32 To determine the effect of RSV on 2-DG-induced
ER stress, NB1691 cells were exposed to 10–100 μM RSV in the
presence or absence of 2-DG for 8 h, and the levels of GRP94,
GRP78 and CHOP were then evaluated using western blot
analysis. As shown in Figure 4c, RSV reduced the 2-DG-
mediated induction of GRP94 and GRP78 but increased CHOP
expression. This result is consistent with potentiation of ER
stress. Recently, it was demonstrated that Akt modulates ER
stress by increasing the expression of GRP78.33 To determine
the role of Akt in 2-DG-induced ER stress, NB1691 cells were
pretreated with the PI3K inhibitor wortmannin and then
exposed to 2-DG for 8 h. The levels of GRP78, GRP94 and
CHOP were then examined using western blot analysis
(Figure 4d). PI3K inhibition prevented the 2-DG-induced
increase in Akt phosphorylation and the level of GRP78.
Simultaneously, PI3K inhibition attenuated the 2-DG-induced
increase in GRP94 but greatly increased the level of CHOP.
These data indicate that Akt enhances the prosurvival arm of
the UPR and conﬁrm that PI3K inhibitors partially mimic RSV
and suggest a mechanism wherein RSV downregulates the UPR
by suppressing the Akt pathway and its activation by 2-DG.
Combined application of 2-DG and RSV induces apoptotic
cell death in NB cells
RSV has been shown to induce both caspase- and calpain-
mediated apoptotic cell death.34 α-Fodrin is a cytoskeletal
protein that is cleaved by both calpains and caspases, and
therefore we used western blot analysis to examine α-fodrin
cleavage in NB1691 cells that were exposed to 2-DG and RSV.
As shown in Figure 5a, combined treatment with RSV and
2-DG generated 150 and 120 kDa fragments that are char-
acteristic of caspase activation, but not the 145 and 150 kDa
fragments that are characteristic of calpain activation. Caspase
activation was conﬁrmed by the presence of cleaved caspase-3
fragments in the lysates of cells exposed to both 2-DG and RSV
but not in lysates of cells exposed to 2-DG alone. To determine
the functional consequences of combined RSV and 2-DG
treatment in NB, NB cell lines were exposed to 0.5 or 2 mM
2-DG in the presence or absence of 10 μM RSV, and viability
was examined after 72 h. Combined treatment with 2-DG and
RSV signiﬁcantly reduced viability compared with treatment
with 2-DG alone in all NB cell lines (Po0.05; n= 3). RSV
decreased viability by an average of 41+6.9% and 41+10% for
cells treated with 0.5 and 2mM 2-DG, respectively (Figure 5b).
RSV-mediated downregulation of Akt is dependent on PP1α
activity but independent of SIRT1
Although RSV is known to downregulate Akt activity, the
mechanism for this action is not clear. However, it may involve
Figure 6 The resveratrol (RSV)-mediated reduction of Akt activation is dependent on protein phosphatase 1α (PP1α) but independent
of SIRT1. (a) NB1691 cells were treated with the PP1α inhibitor tautomycin at the concentrations shown before 8 h of exposure to
2-deoxy-D-glucose (2-DG) and RSV. Akt phosphorylation levels were examined using western blot analysis. (b) NB1691 cells were treated
with the speciﬁc SIRT1 inhibitor EX-527 before 8 h of exposure to 2-DG and RSV. Akt phosphorylation levels were examined using western
blot analysis. (c) To determine the effect of combining 2-DG with RSV on AMPK (AMP-activated protein kinase), NB1691 cells were
treated with 2 mM 2-DG and RSV (10, 25, 50 or 100 μM) for 8 h and the level of ACC phosphorylation examined using western blot
analysis. (d) To examine whether SIRT1 inhibition affected 2-DG+RSV-induced cell death, NB1691 cells were treated with 2-DG+RSV
with or without EX-527, and viability was determined using MTS assays. *Po0.05 compared with treatment with 2-DG alone.
No signiﬁcant difference was observed between 2-DG+RSV-treated and EX-527+2-DG+RSV-treated cells.
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phosphatase activation.34,35 To investigate this possibility, we
quantiﬁed the effects of 2-DG and RSV on PP1 activation by
measuring the phosphorylation status of the catalytic subunit
PP1α. As demonstrated in Figures 5a and b, 2-DG treatment
induced a 3.4-fold increase in the phosphorylation of PP1α at
threonine 380 (T380). Combined treatment with 2-DG and
RSV signiﬁcantly reduced the phosphorylation of PP1α at T380
compared with treatment with 2-DG alone. Phosphorylation of
PP1α at T380 has previously been shown to inhibit phospha-
tase activity,36 suggesting that RSV treatment increases PP1α
activity. To determine whether PP1α activity is necessary for
RSV-mediated downregulation of Akt activity, NB1691 cells
were pretreated with tautomycin, a speciﬁc inhibitor of PP1α,
and then subjected to treatment with 2-DG and RSV, as
described above. The level of Akt phosphorylation was
examined using western blot analysis (Figure 6a). Tautomycin
treatment attenuated RSV-mediated downregulation of Akt
phosphorylation in the presence of 2-DG, consistent with the
hypothesis that PP1α is an intermediate in RSV-mediated
downregulation of Akt. RSV has been shown to activate
members of the silent information regulator family (sirtuins
or SIRTS). SIRTs are NAD-dependent histone deacetylases that
play key roles in cellular stress and aging.37 In 3T3-L1 pre-
adipocytes, RSV-mediated downregulation of Akt was itself
mediated by the activation of AMPK (AMP-activated protein
kinase) and SIRT1.38 RSV has been shown to activate AMPK
that can indirectly regulate SIRT1 activity by modulating
intracellular NAD+ levels.39,40 To determine whether the
SIRT1 activity is required for RSV-mediated downregulation
of Akt, NB1691 cells were pretreated with EX-527, a speciﬁc
SIRT1 inhibitor, and then exposed to 2-DG and RSV, as
described above. As shown in Figure 6b, Akt phosphorylation
was reduced by treatment with RSV+EX527 to levels similar to
those observed following treatment with RSV+vehicle in the
control groups. These data conﬁrm that RSV downregulates
Akt independently of SIRT1. Treatment with 2-DG alone
induced robust activation of AMPK, as indicated by the
increased phosphorylation of acetyl-CoA carboxylase (at
T320), a downstream target of AMPK, whereas treatment with
RSV alone failed to activate AMPK or affect phospho-acetyl-
CoA carboxylase levels, even when it was combined with 2-DG
(Figure 6c). In addition, the potentiating effects of RSV on
2-DG-mediated cytotoxicity were not affected by treatment
with EX-527 (Figure 6d). To conﬁrm EX-527 activity in our
experiments, NB1691 cells were exposed to 10 μM EX-527 for
increasing period of time, and the level of acetylated lysine was
examined using western blot analysis. EX-527 rapidly increased
the levels of acetylated lysine, suggesting that EX-527
did inhibit SIRT1 activity in our cell lines (Supplementary
Figure 5).
DISCUSSION
Our work conﬁrms the results of previous studies indicating
that the glycolytic pathway is a valid target for treatment of NB.
Furthermore, we demonstrate, for the ﬁrst time, that combin-
ing RSV treatment with 2-DG signiﬁcantly reduces NB cell
viability in response to 2-DG by downregulating Akt signaling
and inhibiting the UPR. We independently demonstrate that
these two pathways together confer a survival advantage in
responses to 2-DG, and that inhibiting their activity can
increase the effect of 2-DG on cell viability. We also propose
a novel mechanism of action in which 2-DG inhibits PP1
activity, leading to increased Akt phosphorylation and cell
survival, and we show that RSV restores PP1 activity, leading to
the dephosphorylation of Akt and cell death.
NB is the most common extracranial solid tumor in
children, and it accounts for 15% of pediatric cancer deaths.
Because it originates from the neural crest, it is both clinically
and genetically heterogeneous. The prognosis for high-risk
patients remains poor. Most high-risk NB patients will relapse
after an initial response to therapy, and treatment options are
limited in these patients because of the cumulative toxicities
associated with conventional chemotherapy. Because cancer
cells depend on glucose, the glycolytic pathway has emerged as
an attractive target: damage to normal, less glycolytic cells
should be minimal when using such therapies. Recently, it was
demonstrated that elevated GLUT1 expression was a strong
predictor of NB patient outcomes, suggesting that high-risk
patients might beneﬁt from the use of glycolytic inhibitors.41
Furthermore, Matsushita et al.41 demonstrated that NB cell
lines with high GLUT1 expression were sensitive to the
glycolysis inhibitor 3-bromopyruvate acid. Here, we examined
the effects of 2-DG in six NB cell lines, all of which were
derived from patients with advanced-stage NB. Application of
2-DG decreased cell viability in all of the cell lines, with IC50
values ranging from 1.86 to 5.40mM. We found that the IC50
for most cell lines was ∼ 2mM, within the reported range for
clinically achievable treatments.42 Furthermore, we observed a
signiﬁcant decrease in NB cell viability when 2-DG was applied
at concentrations as low as 0.5 mM. Although these treatments
have been demonstrated to be safe in multiple clinical trials,
2-DG is only minimally effective when used as a single agent.
We therefore sought ways to increase its effectiveness as an NB
therapeutic agent.
The polytrophic nature of RSV makes it appealing because it
can attenuate multiple cancer-promoting pathways.43 Extensive
preclinical analyses have indicated that RSV regulates cell
survival pathways and cell cycle progression in addition to
having effects on tumor cell invasion, metastasis and
angiogenesis.16 In NB, RSV has been shown to induce
apoptotic cell death and decrease tumor volume.17,18 Here,
we found that RSV augmented 2-DG-induced cell death in all
of the NB cell lines that were examined. Furthermore, we
found that in the NB cell line NB1691, a combination
treatment including both 2-DG and RSV induced robust
caspase-3 activity, indicating the activation of apoptotic cell
death pathways. In examining cell survival and cell stress
pathways, we found that RSV potentiated the effects of 2-DG
by modulating the activity of Akt. In our experiments, 2-DG
treatment activated Akt by increasing Akt phosphorylation at
T450, T308 and S473. This effect has previously been observed
in other cancer cell lines, including those derived from breast,
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colorectal and non-small-cell lung cancer.25 DeSalvo et al.24
recently reported that inhibition of Akt sensitized acute
lymphoblastic leukemia cells to 2-DG-induced apoptosis.
Similar to these results, we found that inhibiting Akt greatly
increased 2-DG-induced NB cell death. We also found that
2-DG induced ER stress and UPR, as indicated by observed
increases in the levels of GRP78, GRP94 and CHOP. GRP78
and GRP94 play key roles in mediating cell survival following
ER stress.10 Reducing GRP78 levels using a GRP78-speciﬁc
small interfering RNA signiﬁcantly increased 2-DG-induced
apoptosis in acute lymphoblastic leukemia.24 Because GRP78
inhibitors are not clinically available, we inhibited UPR survival
activity using 17-AAG that inhibits GRP94. In pediatric clinical
trials, 17-AAG was found to be safe and well tolerated.44
Treating NB cells with 17-AAG signiﬁcantly increased
2-DG-induced cell death.
Akt was previously shown to regulate the UPR during ER
stress by promoting the accumulation of GRP78.33 Our data
indicate that in NB cells, Akt increased the accumulation of
GRP78 in response to 2-DG. We found that inhibiting Akt
signaling blocked the 2-DG-induced accumulation of GRP78
and increased CHOP levels. Finally, RSV treatment decreased
Akt phosphorylation and GRP78 and GRP94 levels and
increased the level of CHOP in a dose-dependent manner,
indicating that RSV both attenuates Akt activity and down-
regulates the UPR. Our data suggest that RSV potentiates
2-DG-induced NB cell death by reducing Akt activity and
inhibiting the UPR.
The mechanism by which 2-DG activates Akt has not
been determined. Zhong et al.25 reported that 2-DG-induced
activation of Akt was independent of LBK1/AMPK activation
or glucose inhibition. Some reports have suggested that 2-DG
induces Akt phosphorylation via growth factor receptor-
mediated signaling. Estan et al.45 found that 2-DG induced
the phosphorylation of IGF-1R and the activation of Akt in
myeloid leukemia cell lines. Although we observed a modest
increase in the level of phospho-IRS-1 and an increase in
PI3K binding to IRS-1, which indicates the activation of the
IRS-1/PI3K/Akt pathway, we found that 2-DG, like glucose
deprivation, activated Akt in a serum growth factor-
independent manner. These results are in contrast to a report
by Estan et al.45 who showed that the induction of phospho-
Akt by 2-DG required serum factors. Therefore, the mechan-
ism of Akt activation by 2-DG appears to be cell type
dependent, and it may differ between different types of cancers.
Because the activation of Akt by 2-DG was independent of
growth factor signaling, we next examined the effect of 2-DG
on phosphatase activity. Akt activity is regulated by multiple
phosphatases, including PTEN, PP2a and PP1α, and recent
data have indicated that PP1α is the major phosphatase that
targets Akt at T450 that modulates the activity of Akt.46 PP1α is
a subunit of PP1, and its activity negatively regulates Akt
activation by targeting PDK1 and other kinases, leading to
decreased Akt activity. PP1α was also reported to cause Akt
dephosphorylation and apoptosis in sphingosine-treated
Jurkat cells and geldanamycin-treated breast cancer cells.47,48
We found that 2-DG increased the level of PP1α that was
phosphorylated at T320 that is thought to inactivate PP1α.36
RSV blocked this increase, resulting in attenuated phospho-Akt
levels (Figure 5). This provides a mechanism by which RSV can
mediate Akt dephosphorylation by modulating the phosphatase
activity of PP1 and PP1α. Furthermore, inhibiting PP1α activity
using tautomycin blocked RSV-mediated Akt dephosphoryla-
tion, conﬁrming the role of PP1α. Interestingly, it was recently
reported that 2-DG activated Akt via the NOX4-mediated
generation of H2O2.
49 This is consistent with our ﬁndings
because reactive oxygen species are known to inhibit the
activity of protein phosphatases.50
Many of the health-promoting effects of RSV, including
neuroprotection, have been shown to be mediated by the
activation of SIRT1.51 However, RSV-mediated anticancer
effects have been found to be both SIRT1 dependent and
SIRT1 independent. RSV inhibited gastric cancer cell prolifera-
tion and tumor growth in a SIRT1-dependent manner.52
In NB, RSV inhibited the cell cycle and induced apoptosis
independent of SIRT1.53 Similarly, using the SIRT1-speciﬁc
inhibitor EX-527, we found that RSV decreased phospho-Akt
levels and increased 2-DG-induced cell death independent of
SIRT1 activity, and inhibiting SIRT1 did not affect RSV+2-DG-
induced cell death.
The results of this study indicate that NB cells are sensitive to
clinically relevant concentrations of 2-DG and that the efﬁcacy
of 2-DG is signiﬁcantly increased by the addition of RSV. Our
experiments suggest that the modulation of PP1α activity by
both 2-DG and RSV may be responsible for modulating the
activity of Akt and, therefore, the subsequent 2-DG-induced
ER stress and cell death. To our knowledge, this is the ﬁrst
report to examine the potential of combining 2-DG and RSV,
two relatively nontoxic agents, for NB therapy. We propose a
mechanism by which 2-DG increases Akt activity that can
be quenched by RSV, resulting in much more powerful
cytotoxicity.
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